Real-World Effectiveness of Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma
NCT ID: NCT05024539
Last Updated: 2022-04-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
300 participants
OBSERVATIONAL
2021-06-20
2022-12-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Real World Study of Regogfinib in HCC
NCT05557656
Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC
NCT04718909
Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma
NCT05048017
Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted Therapy
NCT05811481
Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC
NCT05134532
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Regorafenib group
Patients were given only regorafenib orally
nonintervention
Joint group
The patient was treated with regorafenib orally and in combination with other medications
nonintervention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
nonintervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Must have been treated with regorafenib
3. Regorafenib must be used after two lines of standard antitumor therapy
Exclusion Criteria
2. First - or second-line treatment with regorafenib
3. Patients with multiple primary cancers
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Henan Cancer Hospital
OTHER_GOV
Shujun Yang
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shujun Yang
Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shujun Yang
Role: STUDY_DIRECTOR
Henan Cancer Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Henan cancer hosiptal
Zhengzhou, Henan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Shujun Yang, bachelor
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YShujun2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.